Sella Aarrestad Provan

• Provan, Sella Aarrestad; Calogiuri, Giovanna; Litleskare, Sigbjørn; Røset, Linda; Pettersen, Henning & Flaten, Ole E. (2024). Participatory Development of a Virtual Reality Exercise Program for People with Chronic Pain. Games for Health Journal. ISSN 2161-783X.
• Kared, Hassen; Jyssum, Ingrid; Alirezaylavasani, Amin; Egner, Ingrid Marie; The Tran, Trung & Tietze, Lisa [Vis alle 17 forfattere av denne artikkelen] (2024). Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study. Frontiers in Immunology. ISSN 1664-3224. 15. doi: 10.3389/fimmu.2024.1296273.
• Provan, Sella Aarrestad; Ahlfors, F.; Bakland, Gunnstein; Hu, Yi; Kristianslund, E.K. & Ikdahl, Eirik [Vis alle 9 forfattere av denne artikkelen] (2024). A validation of register-derived diagnoses of interstitial lung disease in patients with inflammatory arthritis: data from the NOR-DMARD study. Scandinavian Journal of Rheumatology. ISSN 0300-9742. doi: 10.1080/03009742.2024.2306716.
• Christiansen, Sara Nysom; Horskjær Rasmussen, Simon; Pons, Marion; Michelsen, Brigitte; Glintborg, Bente & Gudbjornsson, Bjorn [Vis alle 33 forfattere av denne artikkelen] (2024). Patient-reported outcomes in axial spondyloarthritis and psoriatic arthritis patients treated with secukinumab for 24 months in daily clinical practice. Seminars in Arthritis & Rheumatism. ISSN 0049-0172. 65. doi: 10.1016/j.semarthrit.2024.152388.
• Gehringer, Celina K.; Martin, Glen P.; Hyrich, Kimme L.; Verstappen, Suzanne M.M.; Sexton, Joseph & Kristianslund, Eirik [Vis alle 9 forfattere av denne artikkelen] (2024). Developing and externally validating multinomial prediction models for methotrexate treatment outcomes in patients with rheumatoid arthritis: results from an international collaboration. Journal of Clinical Epidemiology. ISSN 0895-4356. 166. doi: 10.1016/j.jclinepi.2023.111239.
• Berg, Inger Jorid; Tveter, Anne Therese; Bakland, Gunnstein; Hakim, Sarah; Kristianslund, Eirik & Lillegraven, Siri [Vis alle 15 forfattere av denne artikkelen] (2023). Follow-Up of Patients With Axial Spondyloarthritis in Specialist Health Care With Remote Monitoring and Self-Monitoring Compared With Regular Face-to-Face Follow-Up Visits (the ReMonit Study): Protocol for a Randomized, Controlled Open-Label Noninferiority Trial. JMIR Research Protocols. ISSN 1929-0748. 12(1), s. e52872– e52872. doi: 10.2196/52872. Fulltekst i vitenarkiv
• Konzett, Victoria; Kerschbaumer, Andreas; Smolen, Josef S.; Kristianslund, Eirik Klami; Provan, Sella Aarrestad & Kvien, Tore Kristian Aaserud [Vis alle 7 forfattere av denne artikkelen] (2023). Definition of rheumatoid arthritis flare based on SDAI and CDAI. Annals of the Rheumatic Diseases. ISSN 0003-4967. 83(2), s. 169–176. doi: 10.1136/ard-2023-224742.
• Ikdahl, Eirik; Rollefstad, Silvia Christin Hellerud; Kazemi, Amirhossein; Provan, Sella Aarrestad; Larsen, Trine-Lise & Semb, Anne Grete (2023). Non-steroidal anti-inflammatory drugs and risk of pulmonary embolism in patients with inflammatory joint disease—results from the nationwide Norwegian Cardio-rheuma registry. European Heart Journal (EHJ) - Cardiovascular Pharmacotherapy. ISSN 2055-6837. 10(1), s. 27–34. doi: 10.1093/ehjcvp/pvad078. Fulltekst i vitenarkiv Vis sammendrag

  Aims Patients with inflammatory joint diseases (IJD), including rheumatoid arthritis (RA), psoriatic arthritis (PsA), and axial spondyloarthritis (axSpA) have increased rates of pulmonary embolism (PE). Non-steroidal anti-inflammatory drugs (NSAIDs) use is associated with PE in the general population. Our aim was to evaluate the association between NSAIDs use and PE in IJD patients. Methods and results Using individual-level registry data from the whole Norwegian population, including data from the Norwegian Patient Registry and the Norwegian Prescription Database, we: (1) evaluated PE risk in IJD compared to non-IJD individuals, (2) applied the self-controlled case series method to evaluate if PE risks were associated with use of traditional NSAIDs (tNSAIDs) and selective cox-2 inhibitors (coxibs). After a one-year wash-out period, we followed 4 660 475 adults, including 74 001 with IJD (RA: 39 050, PsA: 20 803, and axSpA: 18 591) for a median of 9.0 years. Crude PE incidence rates per 1000 patient years were 2.02 in IJD and 1.01 in non-IJD individuals. Age and sex adjusted hazard ratios for PE events were 1.57 for IJD patients compared to non-IJD. Incidence rate ratios (IRR) [95% confidence interval (CI)] for PE during tNSAIDs use were 0.78 (0.64–0.94, P = 0.010) in IJD and 1.68 (1.61–1.76, P < 0.001) in non-IJD. IRR (95% CI) for PE during coxibs use was 1.75 (1.10–2.79, P = 0.018) in IJD and 2.80 (2.47–3.18, P < 0.001) for non-IJD. Conclusion Pulmonary embolism rates appeared to be higher in IJD than among non-IJD subjects in our study. Traditional NSAIDs may protect against PE in IJD patients, while coxibs may associated with increased PE risk.

• Uhlig, Till; Karoliussen, Lars Fridtjof; Sexton, Joseph; Provan, Sella Aarrestad; Kvien, Tore Kristian Aaserud & Haavardsholm, Espen A. [Vis alle 7 forfattere av denne artikkelen] (2023). Course and predictors of work productivity in gout - results from the NOR-Gout longitudinal 2-year treat-to-target study. Rheumatology. ISSN 1462-0324. 62(12), s. 3886–3892. doi: 10.1093/rheumatology/kead124. Fulltekst i vitenarkiv Vis sammendrag

  Objectives In patients with gout there is a lack of longitudinal studies on the course of work productivity. We explored longitudinal changes in and predictors of work productivity over 2 years. Methods Patients in the NOR-Gout observational study with a recent gout flare and serum urate (sUA) >360 µmol/l attended tight-control visits during escalating urate lowering therapy according to a treat-to-target strategy. From the Work Productivity and Activity Impairment (WPAI) questionnaire, scores for work productivity and activity impairment were assessed over 2 years together with the Beliefs about Medicines Questionnaire and a variety of demographic and clinical variables. Results At baseline patients had a mean age of 56.4 years and 95% were males. WPAI scores at baseline were 5.0% work missed (absenteeism), 19.1% work impairment (presenteeism), 21.4% overall work impairment and 32.1% activity impairment. Work productivity and activity impairment improved during the first months, and remained stable at 1 and 2 years. Comorbidities were not cross-sectionally associated with WPAI scores at baseline, but predicted worse work impairment and activity impairment at year 1. The Beliefs about Medicines Questionnaire subscale with concerns about medicines at baseline independently predicted worse overall work impairment and worse activity impairment at year 1. Conclusions In patients with gout who were intensively treated to the sUA target, work productivity and activity impairment were largely unchanged and at 1 year predicted by comorbidities and patient concerns about medication.

• Glintborg, Bente; Giuseppe, Daniela Di; Wallman, Johan K.; Provan, Sella Aarrestad; Nordström, Dan & Hokkanen, Anna-Mari [Vis alle 15 forfattere av denne artikkelen] (2023). Is the risk of infection higher during treatment with secukinumab than with TNF inhibitors? An observational study from the Nordic countries. Rheumatology. ISSN 1462-0324. 62(2), s. 647–658. doi: 10.1093/rheumatology/keac358.
• Reppe Moe, Sigrid; Haukeland, Hilde; Brunborg, Cathrine; Botea, Antonela; Damjanic, Nenad & Wivestad, Gro Årthun [Vis alle 14 forfattere av denne artikkelen] (2023). Persisting mortality gap in systemic lupus erythematosus; a population-based study on juvenile- and adult-onset SLE in Norway 1999-2022. Rheumatology. ISSN 1462-0324. doi: 10.1093/rheumatology/kead519. Fulltekst i vitenarkiv Vis sammendrag

  Objective: To estimate mortality and survival rates of systemic lupus erythematosus (SLE) in a contemporary, population-based setting and assess potential influences by time, sex, ethnicity, classification criteria and age at diagnosis. Methods: We assessed mortality and survival in the Nor-SLE cohort, which includes all chart-review confirmed SLE cases resident in Southeast Norway (population 2.9 million) 1999-2017. Study end was at death, emigration, or 1 October 2022. We defined juvenile SLE by age <16 years at diagnosis. For standardized mortality rate (SMR) estimates, we applied 15 population controls per case, all matched for age, sex, residency, and ethnicity. We analyzed survival by Kaplan-Meier and risk factors by cox regression. Results: The Nor-SLE cohort included 1558 SLE cases, of whom 749 were incident and met the 2019 European Alliance of Associations for Rheumatology and American College of Rheumatology (2019-EA) classification criteria. SMR was increased to 1.8 (95% CI 1.6-2.2) in incident adult-onset SLE but did not differ between females and males. Survival rates at 5-, 10-, 15 and 20-years were lower in incident adult-onset SLE than in matched controls. In multivariable analysis, lupus nephritis associated with decreased survival, while sex did not. Separate, long-term mortality analyses in the total Nor-SLE cohort showed that SMR peaked at 7.2 (95% CI 3.3-14) in juvenile-onset SLE (n = 93) and fell gradually by increasing age at SLE diagnosis. Conclusion: This study shows persistence of a mortality gap between adult-onset SLE and controls at population level and provides indications of worryingly high mortality in juvenile-onset SLE.

• Delcoigne, Bénédicte; Provan, Sella Aarrestad; Kristianslund, Eirik; Askling, Johan & Ljung, Lotta (2023). How does current disease activity in rheumatoid arthritis affect the short-term risk of acute coronary syndrome? A clinical register based study from Sweden and Norway. European journal of internal medicine. ISSN 0953-6205. doi: 10.1016/j.ejim.2023.06.013.
• Glintborg, Bente; Di Giuseppe, Daniela; Wallman, Johan Karlsson; Nordström, Dan C; Gudbjornsson, Bjorn & Hetland, Merete Lund [Vis alle 15 forfattere av denne artikkelen] (2023). Uptake and effectiveness of newer biologic and targeted synthetic disease-modifying antirheumatic drugs in psoriatic arthritis: results from five Nordic biologics registries. Annals of the Rheumatic Diseases. ISSN 0003-4967. 82(6), s. 820–828. doi: 10.1136/ard-2022-223650.
• Ullensvang, Gyda; Kringeland, Ester Anne; Ikdahl, Eirik; Provan, Sella Aarrestad; Berg, Inger Jorid & Rollefstad, Silvia Christin Hellerud [Vis alle 10 forfattere av denne artikkelen] (2023). Cardiovascular organ damage in relation to hypertension status in patients with ankylosing spondylitis. Blood Pressure. ISSN 0803-7051. 32(1). doi: 10.1080/08037051.2023.2205956. Fulltekst i vitenarkiv Vis sammendrag

  Purpose Hypertension is a major cardiovascular (CV) risk factor in ankylosing spondylitis (AS) patients. Less is known about the prevalence of CV organ damage in relation to hypertension status in AS patients. Materials and Methods CV organ damage was assessed by echocardiography, carotid ultrasound and pulse wave velocity (PWV) by applanation tonometry in 126 AS patients (mean age 49 ± 12 years, 39% women) and 71 normotensive controls (mean age 47 ± 11 years, 52% women). CV organ damage was defined as presence of abnormal left ventricular (LV) geometry, LV diastolic dysfunction, left atrial (LA) dilatation, carotid plaque or high pulse wave velocity (PWV). Results Thirty-four percent of AS patients had hypertension. AS patients with hypertension were older and had higher C-reactive protein (CRP) levels compared to AS patients without hypertension and controls (p < 0.05). The prevalence of CV organ damage was 84% in AS patients with hypertension, 29% in AS patients without hypertension and 30% in controls (p < 0.001). In multivariable logistic regression analyses, having hypertension was associated with a fourfold increased risk of CV organ damage independent of age, presence of AS, gender, body mass index, CRP, and cholesterol (odds ratio (OR) 4.57, 95% confidence interval (CI) 1.53 to 13.61, p = 0.006). In AS patients, presence of hypertension was the only covariable significantly associated with presence of CV organ damage (OR 4.40, 95% CI 1.40 to 13.84, p = 0.011). Conclusions CV organ damage in AS was strongly associated with hypertension, pointing to the importance of guideline-based hypertension management in AS patients.

• Delcoigne, Benedicte; Kopp, Tine Iskov; Arkema, Elizabeth V.; Hellgren, Karin; Provan, Sella Aarrestad & Relas, Heikki [Vis alle 14 forfattere av denne artikkelen] (2023). Exposure to specific tumour necrosis factor inhibitors and risk of demyelinating and inflammatory neuropathy in cohorts of patients with inflammatory arthritis: a collaborative observational study across five Nordic rheumatology registers. RMD Open. ISSN 2056-5933. 9(1). doi: 10.1136/rmdopen-2022-002924. Fulltekst i vitenarkiv Vis sammendrag

  Objective To compare incidences of neuroinflammatory events, including demyelinating disease (DML), inflammatory polyneuropathies (IPN) and multiple sclerosis (MS), in patients with rheumatoid arthritis (RA) or spondyloarthritis (SpA; including psoriatic arthritis) starting a tumour necrosis factor inhibitor (TNFi), investigating whether monoclonal TNFi antibodies (other TNFis (oTNFis)) confer higher risk than etanercept. Methods This is an observational cohort study including patients from the five Nordic countries starting a TNFi in 2001–2020. Time to first neuroinflammatory event was identified through register linkages. We calculated crude incidence rates (cIR) per 1000 person-years and used multivariable-adjusted Cox regression to compare incidences of neuroinflammatory events overall and for DML, IPN and MS with oTNFi versus etanercept. We further examined individual TNFis and indications. Results 33 883 patients with RA and 28 772 patients with SpA were included, initiating 52 704 and 46 572 treatment courses, respectively. In RA, we observed 135 neuroinflammatory events (65% DML) with cIR of 0.38 with oTNFi and 0.34 with etanercept. The HR of oTNFi versus etanercept was 1.07 (95% CI 0.74 to 1.54) for any neuroinflammatory event, 0.79 (95% CI 0.51 to 1.22) for DML, 2.20 (95% CI 1.05 to 4.63) for IPN and 0.73 (95% CI 0.34 to 1.56) for MS. In SpA, we observed 179 events (78% DML) with cIR of 0.68 with oTNFi and 0.65 with etanercept. The HR for any neuroinflammatory event, DML, IPN and MS was 1.06 (95% CI 0.75 to 1.50), 1.01 (95% CI 0.68 to 1.50), 1.28 (95% CI 0.61 to 2.69) and 0.94 (95% CI0.53 to 1.69), respectively. Conclusion The cIRs of neuroinflammatory events are higher in SpA than in RA, but the choice of specific TNFi does not seem to play an important role in the risk of neuroinflammatory events.

• Cordtz, Rene Lindholm; Askling, Johan; Delcoigne, Benedicte; Smedby, Karin E.; Baecklund, Eva & Ballegaard, Christine [Vis alle 15 forfattere av denne artikkelen] (2022). Haematological malignancies in patients with psoriatic arthritis overall and treated with TNF inhibitors: a Nordic cohort study. RMD Open. ISSN 2056-5933. 8(2). doi: 10.1136/rmdopen-2022-002776.
• Bjørlykke, Kristin H.; Ørbo, Hilde Sofie Sager; Tveter, Anne Therese; Jyssum, Ingrid; Sexton, Joseph & Tran, Trung [Vis alle 21 forfattere av denne artikkelen] (2022). Four SARS-CoV-2 vaccine doses or hybrid immunity in patients on immunosuppressive therapies: a Norwegian cohort study. The Lancet Rheumatology. 5(1), s. e36–e46. doi: 10.1016/S2665-9913(22)00330-7. Vis sammendrag

  Background Data on response and safety of repeated vaccinations and hybrid immunity in patients with immune-mediated inflammatory diseases on immunosuppressive therapy is needed to further develop vaccination strategies in this vulnerable population. This study aimed to evaluate hybrid immunity and humoral immune response and safety of four SARS-CoV-2 vaccine doses in patients with immune-mediated inflammatory diseases on immunosuppressive therapy. Methods This prospective observational Norwegian study of vaccine response to COVID-19 (Nor-vaC) included adult patients aged 18 years and older with immune-mediated inflammatory diseases (rheumatoid arthritis, spondyloarthritis, psoriatic arthritis, Crohn's disease, or ulcerative colitis) on immunosuppressive therapy, who had received four SARS-CoV-2 vaccine doses (vaccine group) or three vaccine doses followed by COVID-19 (hybrid group), and healthy controls receiving three vaccine doses (control group). Patients were recruited from the Division of Rheumatology at Diakonhjemmet Hospital, Oslo, and the Department of Gastroenterology at Akershus University Hospital, Lørenskog. Patients who had COVID-19 before the third vaccine dose, and patients with allergies or intolerances to elements of the vaccine were excluded. Antibodies to the receptor-binding domain of SARS-CoV-2 spike protein (anti-RBD antibodies) were assessed 2–4 weeks following vaccination or COVID-19. This study is registered at Clinialtrials.gov, NCT04798625. Findings Between Nov 12, 2021, and April 19, 2022, 1458 participants with immune-mediated inflammatory diseases provided post-vaccination samples at 2–4 weeks following a third vaccine dose. After 544 participants were excluded, 715 (78%) of the remaining 914 participants received the fourth dose of the vaccine, and of these, 536 (75%) provided post-vaccination samples 2–4 weeks after their fourth vaccination (vaccine group). 199 (22%) of the 914 had COVID-19 after their third dose of the vaccine and of these, 167 (84%) provided samples (hybrid group). 256 of the eligible 703 patients had rheumatoid arthritis, 107 had spondyloarthritis, 115 had psoriatic arthritis, 130 had Crohn's disease, and 95 had ulcerative colitis). Median age was 56 years [IQR 45–65], 398 (57%) were women, and 305 (43%) were men. Patients in the vaccine group had higher anti-RBD antibody concentrations following the fourth vaccine dose (median 6192 BAU/ml [IQR 2878–11 243]) than after the third dose (median 5087 BAU/ml [1250–9081]; p< 0·0001), but lower antibody concentrations than the control group following the third dose (median 7595 BAU/ml [5916–12 001]; p< 0·0001). Antibody concentrations were higher in the patients in the hybrid group (23 548 BAU/ml [IQR 11 440–35 935]) than in the vaccine group (p<0·0001). No difference was found in antibody concentrations between the fourth dose of BNT162b2 (full-dose) and mRNA-1273 (half-dose). Patients and controls had a comparable safety profile after both three and four vaccine doses. Interpretation Vaccine boosters improve humoral immune responses and are safe in patients with immune-mediated inflammatory diseases on immunosuppressive therapy, and administration should be considered regularly in this patient group. Hybrid immunity with omicron induces a strong humoral response suggesting longer intervals between booster doses in this patient group.

• Syversen, Silje Watterdal; Jyssum, Ingrid; Tveter, Anne Therese; Sexton, Joseph; Christensen, Ingrid Egeland & Tran, Trung [Vis alle 20 forfattere av denne artikkelen] (2022). Immunogenicity and safety of a three-dose SARS-CoV-2 vaccination strategy in patients with immune-mediated inflammatory diseases on immunosuppressive therapy. RMD Open. ISSN 2056-5933. 8(2). doi: 10.1136/rmdopen-2022-002417. Fulltekst i vitenarkiv
• Delcoigne, Bénédicte; Provan, Sella Aarrestad; Hammer, Hilde Berner; Di Giuseppe, Daniela; Frisell, Thomas & Glintborg, Bente [Vis alle 13 forfattere av denne artikkelen] (2022). Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration. Rheumatology. ISSN 1462-0324. 61(11), s. 4286–4296. doi: 10.1093/rheumatology/keac081. Fulltekst i vitenarkiv
• Christensen, Ingrid Egeland; Jyssum, Ingrid; Tveter, Anne Therese; Sexton, Joseph; Tran, Trung & Mjaaland, Siri [Vis alle 19 forfattere av denne artikkelen] (2022). The persistence of anti-Spike antibodies following two SARS-CoV-2 vaccine doses in patients on immunosuppressive therapy compared to healthy controls—a prospective cohort study. BMC Medicine. ISSN 1741-7015. 20(1), s. 1–13. doi: 10.1186/s12916-022-02587-8. Fulltekst i vitenarkiv Vis sammendrag

  Background The durability of vaccine-induced humoral immunity against SARS-CoV-2 in patients with immune-mediated inflammatory diseases (IMIDs) on immunosuppressive therapy is not known. The aim of this study was to compare the persistence of anti-Spike antibodies following two-dose SARS-CoV-2 vaccination between IMID patients and healthy controls and to identify factors associated with antibody decline. Methods IMID patients on immunosuppressive medication enrolled in the prospective observational Nor-vaC study were included. Participants received two-dose SARS-CoV-2 vaccination. Serum collected at two time points following vaccination (first assessment within 6–48 days, second within 49–123 days) were analyzed for antibodies binding the receptor-binding domain (RBD) of the SARS-CoV-2 Spike protein. Multivariable regression models estimated percent reduction in anti-RBD over 30 days and factors associated with reduction. Results A total of 1108 patients (403 rheumatoid arthritis, 195 psoriatic arthritis, 195 spondyloarthritis, 124 ulcerative colitis, 191 Crohn’s disease) and 134 controls provided blood samples within the defined intervals (median 19 days [IQR 15–24] and 97 days [87–105] after second vaccine dose). Antibody levels were lower in patients compared to controls at both time points, with median anti-RBD 2806 BAU/ml [IQR 1018–6068] in patients and 6187 BAU/ml [4105–7496] in controls (p<0.001) at first assessment, and 608 BAU/ml [IQR 58–1053] in patients and 1520 BAU/ml [979–3766] in controls (p<0.001) at second assessment. At second assessment, low anti-RBD antibody levels (defined as <200 BAU/ml) were found in 449 (41%) patients, and 6 (5%) controls (p<0.001). The change was − 83% in patients and − 66% in controls (p<0.001). Patients had a greater estimated 30 days percent reduction in anti-RBD levels compared to controls − 4.9 (95% CI − 7.4 to − 2.4), (p<0.05). Among therapies, mono- or combination treatment with tumor necrosis factor inhibitors was associated with the greatest decline. Conclusions Within 4 months after vaccination, antibody levels declined considerably in both IMID patients and controls. Patients had lower initial antibody levels and a more pronounced decline compared to healthy controls and were therefore more likely to decline to low antibody levels. These results support that IMID patients need additional vaccine doses at an earlier stage than healthy individuals.

• Loza, Estibaliz; Carmona, Loreto; Woolf, Anthony; Fautrel, Bruno; Courvoisier, Delphine S & Verstappen, Suzanne [Vis alle 15 forfattere av denne artikkelen] (2022). Implementation of recommendations in rheumatic and musculoskeletal diseases: Considerations for development and uptake. Annals of the Rheumatic Diseases. ISSN 0003-4967. 81(10). doi: 10.1136/ard-2022-223016.
• Di Giuseppe, Daniela; Lindström, Ulf; Aaltonen, Kalle; Relas, Heikki; Provan, Sella Aarrestad & Gudbjornsson, Bjorn [Vis alle 16 forfattere av denne artikkelen] (2022). The occurrence of multiple treatment switches in axial spondyloarthritis. Results from five Nordic rheumatology registries. Rheumatology. ISSN 1462-0324. 61(9), s. 3647–3656. doi: 10.1093/rheumatology/keab946.
• Glintborg, Bente; Lindström, Ulf; Giuseppe, Daniela Di; Provan, Sella Aarrestad; Gudbjornsson, Bjorn & Hetland, Merete Lund [Vis alle 19 forfattere av denne artikkelen] (2022). One-Year Treatment Outcomes of Secukinumab Versus Tumor Necrosis Factor Inhibitors in Spondyloarthritis: Results From Five Nordic Biologic Registries Including More Than 10,000 Treatment Courses. Arthritis care & research. ISSN 2151-464X. 74(5), s. 748–758. doi: 10.1002/acr.24523.
• Syversen, Silje Watterdal; Jyssum, Ingrid; Tveter, Anne Therese; Tran, Trung; Sexton, Joseph & Provan, Sella Aarrestad [Vis alle 22 forfattere av denne artikkelen] (2022). Immunogenicity and Safety of Standard and Third-Dose SARS-CoV-2 Vaccination in Patients Receiving Immunosuppressive Therapy. Arthritis & Rheumatology. ISSN 2326-5191. 74(8), s. 1321–1332. doi: 10.1002/art.42153. Fulltekst i vitenarkiv
• Delcoigne, Benedicte; Ljung, Lotta; Provan, Sella Aarrestad; Glintborg, Bente; Hetland, Merete Lund & Grøn, Kathrine Lederballe [Vis alle 12 forfattere av denne artikkelen] (2022). Short-term, intermediate-term and long-term risks of acute coronary syndrome in cohorts of patients with RA starting biologic DMARDs: Results from four Nordic countries. Annals of the Rheumatic Diseases. ISSN 0003-4967. 81, s. 789–797. doi: 10.1136/annrheumdis-2021-221996.
• Jyssum, Ingrid; Kared, Hassen; Tran, Trung; Tveter, Anne Therese; Provan, Sella Aarrestad & Sexton, Joseph [Vis alle 22 forfattere av denne artikkelen] (2021). Humoral and cellular immune responses to two and three doses of SARS-CoV-2 vaccines in rituximab-treated patients with rheumatoid arthritis: a prospective, cohort study. The Lancet Rheumatology. doi: 10.1016/S2665-9913(21)00394-5. Fulltekst i vitenarkiv
• Tveter, Anne Therese; Provan, Sella Aarrestad; Moholt, Ellen; Bergsmark, Kjetil & Østerås, Nina (2021). Bruk av videokonsultasjon ved en revmatologisk poliklinikk. Tidsskrift for Den norske legeforening. ISSN 0029-2001. 141(8), s. 737–742. doi: 10.4045/tidsskr.20.0882. Vis sammendrag

  På grunn av covid-19-pandemien ble implementering av videokonsultasjon som alternativ til fysisk oppmøte ved polikliniske konsultasjoner fremskyndet for personer med revmatisk sykdom ved Diakonhjemmet Sykehus. Videokonsultasjon ble innført i mars 2020, og vi presenterer her erfaringer blant behandlere og pasienter.

• Chatzidionysiou, Katerina; Hetland, Merete Lund; Frisell, Thomas; Giuseppe, Daniela Di; Hellgren, Karin & Glintborg, Bente [Vis alle 20 forfattere av denne artikkelen] (2021). Effectiveness of a Second Biologic After Failure of a Non–tumor Necrosis Factor Inhibitor As First Biologic in Rheumatoid Arthritis. Journal of Rheumatology. ISSN 0315-162X. 48. doi: 10.3899/jrheum.201467. Vis sammendrag

  Objective: In rheumatoid arthritis (RA), evidence regarding the effectiveness of a second biologic disease-modifying antirheumatic drug (bDMARD) in patients whose first-ever bDMARD was a non-tumor necrosis factor inhibitor (TNFi) bDMARD is limited. The objective of this study was therefore to assess the outcome of a second bDMARD (non-TNFi: rituximab [RTX], abatacept [ABA], or tocilizumab [TCZ], separately; and TNFi) after failure of a non-TNFi bDMARD as first bDMARD. Methods: We identified patients with RA from the 5 Nordic biologics registers who started treatment with a non-TNFi as first-ever bDMARD but switched to a second bDMARD. For the second bDMARD, we assessed drug survival (at 6 and 12 months) and primary response (at 6 months). Results: We included 620 patients starting a second bDMARD (ABA 86, RTX 40, TCZ 67, and TNFi 427) following failure of a first non-TNFi bDMARD. At 6 and 12 months after start of their second bDMARD, approximately 70% and 60%, respectively, remained on treatment, and at 6 months, less than one-third of patients were still on their second bDMARD and had reached low disease activity or remission according to the Disease Activity Score in 28 joints. For those patients whose second bMDARD was a TNFi, the corresponding proportion was slightly higher (40%). Conclusion: The drug survival and primary response of a second bDMARD in patients with RA switching due to failure of a non-TNFi bDMARD as first bDMARD is modest. Some patients may benefit from TNFi when used after failure of a non-TNFi as first bDMARD.

• Christensen, Ingrid Egeland; Lillegraven, Siri; Pawel, Mielnik; Bakland, Gunnstein; Loli, Liz Paucar & Sexton, Joseph [Vis alle 9 forfattere av denne artikkelen] (2021). Serious infections in patients with rheumatoid arthritis and psoriatic arthritis treated with tumour necrosis factor inhibitors: data from register linkage of the NOR-DMARD study. Annals of the Rheumatic Diseases. ISSN 0003-4967. doi: 10.1136/annrheumdis-2021-221007. Fulltekst i vitenarkiv Vis sammendrag

  Objectives: To estimate the incidence of serious infections (SIs) in patients with rheumatoid arthritis (RA) and psoriatic arthritis (PsA) treated with tumour necrosis factor inhibitor (TNFi), and compare risk of SIs between patients with RA and PsA. Methods: We included patients with RA and PsA from the NORwegian-Disease Modifying Anti-Rheumatic Drug registry starting TNFi treatment. Crude incidence rates (IRs) and IR ratio for SIs were calculated. The risk of SIs in patients with RA and PsA was compared using adjusted Cox-regression models. Results: A total of 3169 TNFi treatment courses (RA/PsA: 1778/1391) were identified in 2359 patients. Patients with RA were significantly older with more extensive use of co-medication. The crude IRs for SIs were 4.17 (95% CI 3.52 to 4.95) in patients with RA and 2.16 (95% CI 1.66 to 2.81) in patients with PsA. Compared with the patients with RA, patients with PsA had a lower risk of SIs (HR 0.59, 95% CI 0.41 to 0.85, p=0.004) in complete set analysis. The reduced risk in PsA versus RA remained significant after multiple adjustments and consistent across strata based on age, gender and disease status. Conclusions: Compared with patients with RA, the risk of SIs was significantly lower in patients with PsA during TNFi exposure. Methods We included patients with RA and PsA from the NORwegian-Disease Modifying Anti-Rheumatic Drug registry starting TNFi treatment. Crude incidence rates (IRs) and IR ratio for SIs were calculated. The risk of SIs in patients with RA and PsA was compared using adjusted Cox-regression models. Results A total of 3169 TNFi treatment courses (RA/ PsA: 1778/1391) were identified in 2359 patients. Patients with RA were significantly older with more extensive use of co-medication. The crude IRs for SIs were 4.17 (95% CI 3.52 to 4.95) in patients with RA and 2.16 (95% CI 1.66 to 2.81) in patients with PsA. Compared with the patients with RA, patients with PsA had a lower risk of SIs (HR 0.59, 95% CI 0.41 to 0.85, p=0.004) in complete set analysis. The reduced risk in PsA versus RA remained significant after multiple adjustments and consistent across strata based on age, gender and disease status. Conclusions Compared with patients with RA, the risk of SIs was significantly lower in patients with PsA during TNFi exposure.

• Haugmark, Trond; Hagen, Kåre Birger; Provan, Sella Aarrestad; Smedslund, Geir & Zangi, Heidi A (2021). Effects of a mindfulness-based and acceptance-based group programme followed by physical activity for patients with fibromyalgia: a randomised controlled trial. BMJ Open. ISSN 2044-6055. 11(6). doi: 10.1136/bmjopen-2020-046943. Fulltekst i vitenarkiv
• Provan, Sella A.; Dean, Linda E.; Jones, Gareth & Macfarlane, Gary J. (2021). The changing states of fibromyalgia in patients with axial spondyloarthritis: results from the British Society of Rheumatology Biologics Register for Ankylosing Spondylitis. Rheumatology. ISSN 1462-0324. 60(9), s. 4121–4129. doi: 10.1093/rheumatology/keaa888.
• Hellgren, Karin; Ballegaard, Christine; Delcoigne, Bénédicte; Cordtz, René; Nordström, Dan C. & Aaltonen, Kalle [Vis alle 14 forfattere av denne artikkelen] (2021). Risk of solid cancers overall and by subtypes in patients with psoriatic arthritis treated with TNF inhibitors - a Nordic cohort study. Rheumatology. ISSN 1462-0324. 60(8), s. 3656–3668. doi: 10.1093/rheumatology/keaa828.
• Haugmark, Trond; Hagen, Kåre Birger; Provan, Sella Aarrestad; Sexton, Joseph & Zangi, Heidi Andersen (2021). Trajectories of change in symptom severity in patients with fibromyalgia: exploratory analyses of a randomised controlled trial. Rheumatology International. ISSN 0172-8172. 41, s. 691–697. doi: 10.1007/s00296-021-04801-x. Fulltekst i vitenarkiv
• Lund Hansen, Rebekka; Schoedt Jørgensen, Tanja; Dreyer, Lene; Hetland, Merete Lund; Glintborg, Bente & Askling, Johan [Vis alle 17 forfattere av denne artikkelen] (2021). Inflammatory hallmarks of lesser prominence in psoriatic arthritis patients starting biologics: A Nordic population-based cohort study. Rheumatology. ISSN 1462-0324. 60(1), s. 140–146. doi: 10.1093/rheumatology/keaa237.
• Chatzidionysiou, Katerina; Delcoigne, Bénédicte; Frisell, Thomas; Hetland, Merete L.; Glintborg, Bente & Dreyer, Lene [Vis alle 15 forfattere av denne artikkelen] (2020). How do we use biologics in rheumatoid arthritis patients with a history of malignancy? An assessment of treatment patterns using Scandinavian registers. RMD Open. ISSN 2056-5933. 6(2). doi: 10.1136/rmdopen-2020-001363.
• Lindström, Ulf; Glintborg, Bente; Di Giuseppe, Daniela; Jørgensen, Tanja Schjødt; Gudbjornsson, Bjorn & Grøn, Kathrine Lederballe [Vis alle 17 forfattere av denne artikkelen] (2020). Comparison of treatment retention and response to secukinumab versus tumour necrosis factor inhibitors in psoriatic arthritis. Rheumatology. ISSN 1462-0324. doi: 10.1093/rheumatology/keaa825.
• Sveaas, Silje Halvorsen; Dagfinrud, Hanne; Berg, Inger Jorid; Provan, Sella Aarrestad; Johansen, Melissa Woll & Pedersen, Elisabeth Alexandersen [Vis alle 7 forfattere av denne artikkelen] (2020). High-Intensity Exercise Improves Fatigue, Sleep, and Mood in Patients With Axial Spondyloarthritis: Secondary Analysis of a Randomized Controlled Trial. Physical Therapy. ISSN 0031-9023. 100(8), s. 1323–1332. doi: 10.1093/ptj/pzaa086. Fulltekst i vitenarkiv
• Provan, Sella Aarrestad; Michelsen, Brigitte; Sexton, Joseph; Uhlig, Till & Hammer, Hilde Berner (2020). Trajectories of fatigue in actively treated patients with established rheumatoid arthritis starting biologic DMARD therapy. RMD Open. ISSN 2056-5933. 6(3). doi: 10.1136/rmdopen-2020-001372.
• Hammer, Hilde Berner; Michelsen, Brigitte; Sexton, Joe; Uhlig, Till & Provan, Sella Aarrestad (2020). Fatigue is cross-sectionally not associated with objective assessments of inflammation, but changes in fatigue are associated with changes of disease activity assessments during biologic treatment of patients with established rheumatoid arthritis. Clinical Rheumatology. ISSN 0770-3198. s. 1–11. doi: 10.1007/s10067-020-05402-y. Fulltekst i vitenarkiv
• Provan, Sella Aarrestad; Lillegraven, Siri; Sexton, Joseph; Angel, Kristin; Austad, Cathrine & Haavardsholm, Espen A. [Vis alle 8 forfattere av denne artikkelen] (2019). Trends in All-Cause and Cardiovascular Mortality in Patients With Incident Rheumatoid Arthritis: A 20-year Follow-Up Matched Case-Cohort Study. Rheumatology. ISSN 1462-0324. doi: 10.1093/rheumatology/kez371. Fulltekst i vitenarkiv
• Lindström, Ulf; Glintborg, Bente; Di Giuseppe, Daniela; Nordström, Dan C.; Provan, Sella Aarrestad & Gudbjörnsson, Björn [Vis alle 12 forfattere av denne artikkelen] (2019). Treatment retention of infliximab and etanercept originators versus their corresponding biosimilars: Nordic collaborative observational study of 2334 biologics naive patients with spondyloarthritis. RMD Open. ISSN 2056-5933. 5(2). doi: 10.1136/rmdopen-2019-001079.
• Provan, Sella Aarrestad; Rollefstad, Silvia Christin Hellerud; Ikdahl, Eirik; Mathiessen, Alexander; Berg, Inger Jorid & Wilkinson, I. B. [Vis alle 12 forfattere av denne artikkelen] (2019). Biomarkers of cardiovascular risk across phenotypes of osteoarthritis. Biomed Central Rheumatology. ISSN 2520-1026. 3(33). doi: 10.1186/s41927-019-0081-8.
• Hammer, Hilde Berner; Michelsen, Brigitte; Sexton, Joseph; Haugen, Ida Kristin; Provan, Sella Aarrestad & Haavardsholm, Espen A. [Vis alle 8 forfattere av denne artikkelen] (2019). Swollen, but not tender joints, are independently associated with ultrasound synovitis: Results from a longitudinal observational study of patients with established rheumatoid arthritis. Annals of the Rheumatic Diseases. ISSN 0003-4967. 78, s. 1179–1185. doi: 10.1136/annrheumdis-2019-215321.
• Sveaas, Silje Halvorsen; Bilberg, Annelie; Berg, Inger Jorid; Provan, Sella Aarrestad; Rollefstad, Silvia Christin Hellerud & Semb, Anne Grete [Vis alle 10 forfattere av denne artikkelen] (2019). High intensity exercise for 3 months reduces disease activity in axial spondyloarthritis (axSpA): A multicentre randomised trial of 100 patients. British Journal of Sports Medicine. ISSN 0306-3674. doi: 10.1136/bjsports-2018-099943.
• Provan, Sella Aarrestad; Austad, Cathrine; Halsaa, Vera; Hammer, Hilde Berner; Kvien, Tore Kristian & Uhlig, Till (2019). Fibromyalgia in patients with rheumatoid arthritis. A 10-year follow-up study, results from the Oslo Rheumatoid Arthritis Register. Clinical and Experimental Rheumatology. ISSN 0392-856X. 37(Supplement 116), s. S58–S62.
• Joseph, Kenth-Louis Hansen; Hagen, Kåre Birger; Tveter, Anne Therese; Magnusson, Karin; Provan, Sella Aarrestad & Dagfinrud, Hanne (2019). Osteoarthritis-Related Walking Disability and Arterial Stiffness: Results From a Cross-Sectional Study. Arthritis care & research. ISSN 2151-464X. 71(2), s. 252–258. doi: 10.1002/acr.23697.
• Glintborg, Bente; Lindström, Ulf; Aaltonen, Kalle; Kristianslund, Eirik; Guðbjörnsson, Björn & Chatzidionysiou, Katerina [Vis alle 28 forfattere av denne artikkelen] (2018). Biological treatment in ankylosing spondylitis in the Nordic countries during 2010-2016: a collaboration between five biological registries. Scandinavian Journal of Rheumatology. ISSN 0300-9742. 47(6), s. 465–474. doi: 10.1080/03009742.2018.1444199.
• Hammer, Hilde Berner; Michelsen, Brigitte; Provan, Sella Aarrestad; Sexton, Joseph; Lampa, Jon & Uhlig, Till [Vis alle 7 forfattere av denne artikkelen] (2018). Tender joint count may not reflect inflammatory activity in established rheumatoid arthritis patients: results from a longitudinal study. Arthritis care & research. ISSN 2151-464X. doi: 10.1002/acr.23815.
• Berg, Inger Jorid; Semb, Anne Grete; Sveaas, Silje Halvorsen; Fongen, Camilla; Heijde, Desirée van der & Kvien, Tore Kristian [Vis alle 8 forfattere av denne artikkelen] (2018). Associations Between Cardiorespiratory Fitness and Arterial Stiffness in Ankylosing Spondylitis: A Cross-sectional Study. Journal of Rheumatology. ISSN 0315-162X. 45(11), s. 1522–1525. doi: 10.3899/jrheum.170726.
• Haugmark, Trond; Hagen, Kåre Birger; Provan, Sella Aarrestad; Bærheim, Elisebeth & Zangi, Heidi Andersen (2018). Effects of a community-based multicomponent rehabilitation programme for patients with fibromyalgia: protocol for a randomised controlled trial. BMJ Open. ISSN 2044-6055. 8(6). doi: 10.1136/bmjopen-2017-021004. Fulltekst i vitenarkiv
• Chatzidionysiou, Katerina; Hetland, Merete Lund; Frisell, Thomas; Giuseppe, Daniela Di; Hellgren, Karin & Glintborg, Bente [Vis alle 18 forfattere av denne artikkelen] (2018). Opportunities and challenges for real-world studies on chronic inflammatory joint diseases through data enrichment and collaboration between national registers: the Nordic example. RMD Open. ISSN 2056-5933. 4. doi: 10.1136/rmdopen-2018-000655.
• Uhlig, Till & Provan, Sella Aarrestad (2018). Treating fatigue in rheumatoid arthritis: does patient age matter? Drugs & Aging. ISSN 1170-229X. 35(10), s. 871–876. doi: 10.1007/s40266-018-0589-4.
• Provan, Sella Aarrestad; Olstad, Daniela Schäfer; Solberg, Erik Ekker; Smedslund, Geir & Dagfinrud, Hanne (2017). Evidence of reduced parasympathetic autonomic regulation in inflammatory joint disease: A meta-analyses study. Seminars in Arthritis & Rheumatism. ISSN 0049-0172. 48(1), s. 134–140. doi: 10.1016/j.semarthrit.2017.11.010.
• Provan, Sella Aarrestad; Olsen, Inge Christoffer; Austad, Cathrine; Haugeberg, Glenn; Kvien, Tore Kristian & Uhlig, Till (2017). Calcium supplementation and inflammation increase mortality in rheumatoid arthritis: A 15-year cohort study in 609 patients from the Oslo Rheumatoid Arthritis Register. Seminars in Arthritis & Rheumatism. ISSN 0049-0172. 46(4), s. 411–417. doi: 10.1016/j.semarthrit.2016.07.011.
• Ikdahl, Eirik; Rollefstad, Silvia Christin Hellerud; Wibetoe, Grunde; Olsen, Inge Christoffer; Berg, Inger Jorid & Hisdal, Jonny [Vis alle 11 forfattere av denne artikkelen] (2016). Predictive value of arterial stiffness and subclinical carotid atherosclerosis for cardiovascular disease in patients with rheumatoid arthritis. Journal of Rheumatology. ISSN 0315-162X. 43(9), s. 1622–1630. doi: 10.3899/jrheum.160053.
• Berg, Inger Jorid; Semb, Anne Grete; Heijde, Desirée van der; Kvien, Tore Kristian; Olsen, Inge Christoffer & Dagfinrud, Hanne [Vis alle 7 forfattere av denne artikkelen] (2015). CRP and ASDAS are associated with future elevated arterial stiffness, a risk marker of cardiovascular disease, in patients with ankylosing spondylitis: Results after 5-year follow-up. Annals of the Rheumatic Diseases. ISSN 0003-4967. 74(8), s. 1562–1566. doi: 10.1136/annrheumdis-2014-206773.
• Berg, Inger Jorid; Heijde, Desirée van der; Dagfinrud, Hanne; Seljeflot, Ingebjørg; Olsen, Inge Christoffer & Kvien, Tore Kristian [Vis alle 8 forfattere av denne artikkelen] (2015). Disease activity in ankylosing spondylitis and associations to markers of vascular pathology and traditional cardiovascular disease risk factors: A cross-sectional study. Journal of Rheumatology. ISSN 0315-162X. 42(4), s. 645–653. doi: 10.3899/jrheum.141018.
• Provan, Sella Aarrestad; Berg, Inger Jorid; Hammer, Hilde Berner; Mathiessen, Alexander; Kvien, Tore Kristian & Semb, Anne Grete (2015). The impact of newer biological disease modifying anti-rheumatic drugs on cardiovascular risk factors: A 12-month longitudinal study in rheumatoid arthritis patients treated with rituximab, abatacept and tociliziumab. PLOS ONE. ISSN 1932-6203. 10:e0130709(6). doi: 10.1371/journal.pone.0130709.
• Sveaas, Silje Halvorsen; Berg, Inger Jorid; Provan, Sella Aarrestad; Semb, Anne Grete; Olsen, Inge Christoffer & Ueland, Thor [Vis alle 11 forfattere av denne artikkelen] (2015). Circulating levels of inflammatory cytokines and cytokine receptors in patients with ankylosing spondylitis: A cross-sectional comparative study. Scandinavian Journal of Rheumatology. ISSN 0300-9742. 44(2), s. 118–124. doi: 10.3109/03009742.2014.956142.
• Sveaas, Silje Halvorsen; Berg, Inger Jorid; Provan, Sella Aarrestad; Semb, Anne Grete; Hagen, Kåre Birger & Vøllestad, Nina Køpke [Vis alle 13 forfattere av denne artikkelen] (2014). Efficacy of High Intensity Exercise on Disease Activity and Cardiovascular Risk in Active Axial Spondyloarthritis: A Randomized Controlled Pilot Study. PLOS ONE. ISSN 1932-6203. 9(9). doi: 10.1371/journal.pone.0108688.
• Berg, Inger Jorid; Semb, Anne Grete; Heijde, Desirée van der; Kvien, Tore Kristian; Hisdal, Jonny & Olsen, Inge Christoffer [Vis alle 8 forfattere av denne artikkelen] (2014). Uveitis is associated with hypertension and atherosclerosis in patients with ankylosing spondylitis: A cross-sectional study. Seminars in Arthritis & Rheumatism. ISSN 0049-0172. 44(3), s. 309–313. doi: 10.1016/j.semarthrit.2014.05.017.
• Navarro-Compan, Victoria; Landewé, Robert; Provan, Sella Aarrestad; Ødegård, Sigrid; Uhlig, Till & Kvien, Tore Kristian [Vis alle 9 forfattere av denne artikkelen] (2014). Relationship between types of radiographic damage and disability in patients with rheumatoid arthritis in the EURIDISS cohort: a longitudinal study. Rheumatology. ISSN 1462-0324. 54(1), s. 83–90. doi: 10.1093/rheumatology/keu284.
• Østerås, Nina; Risberg, May Arna; Kvien, Tore Kristian; Engebretsen, Lars; Nordsletten, Lars & Bruusgaard, Dag [Vis alle 22 forfattere av denne artikkelen] (2013). Hand, hip and knee osteoarthritis in a Norwegian population-based study - The MUST protocol. BMC Musculoskeletal Disorders. ISSN 1471-2474. doi: 10.1186/1471-2474-14-201. Vis sammendrag

  Abstract Background Knowledge about the prevalence and consequences of osteoarthritis (OA) in the Norwegian population is limited. This study has been designed to gain a greater understanding of musculoskeletal pain in the general population with a focus on clinically and radiologically confirmed OA, as well as risk factors, consequences, and management of OA. Methods/Design The Musculoskeletal pain in Ullensaker STudy (MUST) has been designed as an observational study comprising a population-based postal survey and a comprehensive clinical examination of a sub-sample with self-reported OA (MUST OA cohort). All inhabitants in Ullensaker municipality, Norway, aged 40 to 79 years receive the initial population-based postal survey questionnaire with questions about life style, general health, musculoskeletal pain, self-reported OA, comorbidities, health care utilisation, medication use, and functional ability. Participants who self-report OA in their hip, knee and/or hand joints are asked to attend a comprehensive clinical examination at Diakonhjemmet Hospital, Oslo, including a comprehensive medical examination, performance-based functional tests, different imaging modalities, cardiovascular assessment, blood and urine samples, and a number of patient-reported questionnaires including five OA disease specific instruments. Data will be merged with six national data registries. A subsample of those who receive the questionnaire has previously participated in postal surveys conducted in 1990, 1994, and 2004 with data on musculoskeletal pain and functional ability in addition to demographic characteristics and a number of health related factors. This subsample constitutes a population based cohort with 20 years follow-up. Discussion This protocol describes the design of an observational population-based study that will involve the collection of data from a postal survey on musculoskeletal pain, and a comprehensive clinical examination on those with self-reported hand, hip and/or knee OA. These data, in addition to data from national registries, will provide unique insights into clinically and radiologically confirmed OA with respect to risk factors, consequences, and management. Keywords: Osteoarthritis; Hand; Hip; Knee; Observational study; Study protocol

• Halvorsen, Silje; Vøllestad, Nina Køpke; Provan, Sella Aarrestad; Semb, Anne Grete; van der Heijde, Désirée & Hagen, Kåre Birger [Vis alle 7 forfattere av denne artikkelen] (2013). Cardiorespiratory Fitness and Cardiovascular Risk in Patients With Ankylosing Spondylitis: A Cross-Sectional Comparative Study. Arthritis Care and Research. ISSN 0893-7524. 65(6), s. 969–976. doi: 10.1002/acr.21926.
• Mæhlen, Marthe Thoresen; Provan, Sella Aarrestad; de Rooy, Diederik P.C.; van der Helm-van Mil, Annette H.M.; Krabben, Annemarie & Saxne, Tore [Vis alle 14 forfattere av denne artikkelen] (2013). Associations between APOE Genotypes and Disease Susceptibility, Joint Damage and Lipid Levels in Patients with Rheumatoid Arthritis. PLOS ONE. ISSN 1932-6203. 8(4). doi: 10.1371/journal.pone.0060970.
• Semb, Anne Grete; Rollefstad, Silvia Christin Hellerud; Provan, Sella Aarrestad; Kvien, Tore Kristian; Stranden, Einar & Olsen, Inge Christoffer [Vis alle 7 forfattere av denne artikkelen] (2013). Carotid Plaque Characteristics and Disease Activity in Rheumatoid Arthritis. Journal of Rheumatology. ISSN 0315-162X. 40(4), s. 359–368. doi: 10.3899/jrheum.120621. Vis sammendrag

  Objective. Carotid plaques (CP) are predictive of acute coronary syndrome in patients with rheumatoid arthritis (RA), suggesting that atherosclerotic plaques in these patients are vulnerable. The objective of our study was to characterize vulnerability of CP in patients with RA compared to a control population, and between RA patients with different levels of disease activity. Methods. Ultrasound examination of carotid arteries was performed in 152 patients with RA and 89 controls. CP echolucency was evaluated by the Gray-Scale Median (GSM) technique. Lower GSM values indicate higher vulnerability of plaques. CP characteristics were compared between RA patients with active disease and in remission, and between patients and controls. All analyses were performed with adjustment for confounding factors (sex, age, smoking, and blood pressure). Poisson regression analysis was used for count data, mixed modeling for GSM and area per plaque, and analysis of covariance for minimum GSM value per patient. Results. Patients with RA more frequently had CP (median 2, range 0, 4) compared with controls (median 1, range 0, 3; p < 0.001), after adjustment for age and sex. Patients with active RA disease according to the Clinical Disease Activity Index (CDAI) had lower median GSM (p = 0.03), minimum GSM (p = 0.03), and a larger CP area (although the latter finding was not significant; p = 0.27), compared with patients with RA in remission. These findings were not confirmed for other disease measures (Simplified Disease Activity Index, Disease Activity Score-28, C-reactive protein, erythrocyte sedimentation rate). Conclusion. Patients with RA had more CP compared with controls and patients in CDAI remission, and controls had more stable CP than patients with active disease; these findings point to the importance of achieving remission in RA.

• Angel, Kristin; Provan, Sella Aarrestad; Mowinckel, Petter ; Seljeflot, Ingebjørg; Kvien, Tore Kristian & Atar, Dan (2012). The L-arginine/asymmetric dimethylarginine ratio is improved by anti-Tumor Necrosis Factor-alpha therapy in inflammatory arthropathies. Associations with aortic stiffness. Atherosclerosis. ISSN 0021-9150. 225(1), s. 160–165. doi: 10.1016/j.atherosclerosis.2012.08.033.
• Angel, Kristin; Provan, Sella Aarrestad; Fagerhol, Magne Kristoffer; Mowinckel, Petter ; Kvien, Tore Kristian & Atar, Dan (2012). Effect of 1-Year Anti-TNF-alpha Therapy on Aortic Stiffness, Carotid Atherosclerosis, and Calprotectin in Inflammatory Arthropathies: A Controlled Study. American Journal of Hypertension. ISSN 0895-7061. 25(6), s. 644–650. doi: 10.1038/ajh.2012.12.
• Halvorsen, Silje; Vøllestad, Nina Køpke; Fongen, Camilla; Provan, Sella Aarrestad; Semb, Anne Grete & Hagen, Kåre Birger [Vis alle 7 forfattere av denne artikkelen] (2012). Physical Fitness in Patients With Ankylosing Spondylitis: Comparison With Population Controls. Physical Therapy. ISSN 0031-9023. 92(2), s. 298–309. doi: 10.2522/ptj.20110137.
• Halvorsen, Silje; Vøllestad, Nina Køpke; Provan, Sella Aarrestad; Semb, Anne Grete; van der Heijde, Désirée & Hagen, Kåre Birger [Vis alle 7 forfattere av denne artikkelen] (2012). High cardiorespiratory fitness is related to lower cardiovascular risk in patients with ankylosing spondylitis. Arthritis Care and Research. ISSN 0893-7524. doi: 10.1002/acr.21925.
• Provan, Sella Aarrestad; Semb, Anne Grete; Hisdal, Jonny; Stranden, Einar; Agewall, Stefan & Dagfinrud, Hanne [Vis alle 9 forfattere av denne artikkelen] (2011). Remission is the goal for cardiovascular risk management in patients with rheumatoid arthritis: a cross-sectional comparative study. Annals of the Rheumatic Diseases. ISSN 0003-4967. 70(5), s. 812–817. doi: 10.1136/ard.2010.141523.
• Angel, Kristin; Provan, Sella Aarrestad; Hammer, Hilde Berner; Mowinckel, Petter ; Kvien, Tore Kristian & Atar, Dan (2011). Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies. Fundamental & Clinical Pharmacology. ISSN 0767-3981. 25(4), s. 511–517. doi: 10.1111/j.1472-8206.2010.00872.x.
• Provan, Sella Aarrestad; Angel, Kristin; Semb, Anne Grete; Mowinckel, Petter ; Agewall, Stefan & Atar, Dan [Vis alle 7 forfattere av denne artikkelen] (2011). Early Prediction of Increased Arterial Stiffness in Patients with Chronic Inflammation: A 15-year Followup Study of 108 Patients with Rheumatoid Arthritis. Journal of Rheumatology. ISSN 0315-162X. 38(4), s. 606–612. doi: 10.3899/jrheum.100689.
• Peters, Mike J.L.; Symmons, Deborah P.M.; McCarey, David; Dijkmans, Ben A.C.; Nicola, Paulo & Kvien, Tore Kristian [Vis alle 18 forfattere av denne artikkelen] (2010). EULAR evidence-based recommendations for cardiovascular risk management in patients with rheumatoid arthritis and other forms of inflammatory arthritis. Annals of the Rheumatic Diseases. ISSN 0003-4967. 69(2), s. 325–331. doi: 10.1136/ard.2009.113696.
• Angel, Kristin; Provan, Sella Aarrestad; Hammer, Hilde Berner; Mowinckel, Petter; Kvien, Tore Kristian & Atar, Dan (2010). Changes in arterial stiffness during continued infliximab treatment in patients with inflammatory arthropathies. Fundamental & Clinical Pharmacology. ISSN 0767-3981. doi: 10.1111/j.1472-8206.2010.00872.x.
• Provan, Sella Aarrestad; Angel, Kristin; Semb, Anne Grete; Atar, Dan & Kvien, Tore Kristian (2010). NT-proBNP predicts mortality in patients with rheumatoid arthritis: results from 10-year follow-up of the EURIDISS study. Annals of the Rheumatic Diseases. ISSN 0003-4967. 69(11), s. 1946–1950. doi: 10.1136/ard.2009.127704.
• Angel, Kristin; Provan, Sella Aarrestad; Gulseth, Hanne Løvdal; Mowinckel, Petter; Kvien, Tore Kristian & Atar, Dan (2010). Tumor Necrosis Factor-alpha Antagonists Improve Aortic Stiffness in Patients With Inflammatory Arthropathies A Controlled Study. Hypertension. ISSN 0194-911X. 55(2), s. 333–338. doi: 10.1161/HYPERTENSIONAHA.109.143982.

Se alle arbeider i Cristin

• Provan, Sella Aarrestad (2023). P-pille kan gi leddgiktbeskyttelse. [Avis]. VG online og papirutgave.
• Nordberg, Lena Bugge; Schrumpf, Marte; Kristianslund, Eirik; Lillejordet, Even; Provan, Sella Aarrestad & Lillegraven, Siri (2023). Rheumatology congresses post COVID-19: we cannot regress. The Lancet Rheumatology. doi: 10.1016/S2665-9913(23)00153-4.
• Delcoigne, Bénédicte; Provan, Sella Aarrestad; Hammer, Hilde Berner; Di Giuseppe, Daniela; Frisell, Thomas & Glintborg, Bente [Vis alle 13 forfattere av denne artikkelen] (2022). Erratum: Correction to: Do patient-reported measures of disease activity in rheumatoid arthritis vary between countries? Results from a Nordic collaboration (Rheumatology (Oxford, England) (2022) 61 11 (4286-4296)). Rheumatology. ISSN 1462-0324. 61(12). doi: 10.1093/rheumatology/keac151.
• Zangi, Heidi Andersen; Haugmark, Trond; Provan, Sella Aarrestad & Hagen, Kåre Birger (2022). High symptom burden and limited changes in fibromyalgia patients’ health status two years after participation in a multicomponent rehabilitation programme.
• Provan, Sella Aarrestad & Litleskare, Sigbjørn (2022). Skal finne ut om studenter endrer vekt og livsstil. [Internett]. NRK.
• Provan, Sella Aarrestad & Litleskare, Sigbjørn (2022). Forsker på om førsteårsstudenter legger på seg. [Radio]. NRK.
• Provan, Sella Aarrestad; Berg, Inger Jorid; Haugmark, Trond & Zangi, Heidi Andersen (2021). The referral of patients with fibromyalgia to a rheumatological specialist care unit. Is it necessary? Clinical and Experimental Rheumatology. ISSN 0392-856X. 39(3).
• Berg, Inger Jorid & Provan, Sella A. (2021). Inflammatory joint diseases and risk of cardiovascular disease in modern rheumatology. Journal of Rheumatology. ISSN 0315-162X. 48(3), s. 311–313. doi: 10.3899/JRHEUM.201134.
• Provan, Sella Aarrestad; Olstad, Daniela Schäfer; Solberg, Erik Ekker; Smedslund, Geir & Dagfinrud, Hanne (2017). Heart rate variability in inflammatory joint disease: a meta-analysis.
• Sveaas, Silje Halvorsen; Berg, Inger Jorid; Fongen, Camilla; Provan, Sella Aarrestad & Dagfinrud, Hanne (2017). High-intensity cardiorespiratory and strength exercises reduced emotional distress and fatigue in patients with axial spondyloarthritis: a randomized controlled pilot study. Scandinavian Journal of Rheumatology. ISSN 0300-9742. doi: 10.1080/03009742.2017.1347276.
• Mæhlen, Marthe Thoresen; Provan, Sella Aarrestad; Semb, Anne Grete; Uhlig, Till; Heijde, Desirée van der & Olsen, IC [Vis alle 8 forfattere av denne artikkelen] (2012). Apoe genotypes are associated with reduced joint damage and increased lipid levels in patients with rheumatoid arthritis. Annals of the Rheumatic Diseases. ISSN 0003-4967.
• Berg, Inger Jorid; Semb, Anne Grete; Provan, Sella Aarrestad; Dagfinrud, Hanne ; Heijde, Desirée van der & Kvien, Tore Kristian (2012). Cardiovascular disease is related to disease activity in ankylosing spondylitis. Annals of the Rheumatic Diseases. ISSN 0003-4967.
• Berg, Inger Jorid; Provan, Sella Aarrestad; Dagfinrud, Hanne ; van der Heijde, D.M.F.M.; Kvien, Tore Kristian & Semb, Anne Grete (2011). Increased Risk of Cardiovascular Disease in Patients with Active Ankylosing Spondylitis. Arthritis and Rheumatism. ISSN 0004-3591. 63(10), s. S197–S197.
• Angel, Kristin; Provan, Sella Aarrestad; Fagerhol, Magne K.; Kvien, Tore Kristian & Atar, Dan (2010). IMPROVEMENT IN AORTIC STIFFNESS DURING ANTI-TUMOR NECROSIS FACTOR-ALPHA THERAPY IN PATIENTS WITH INFLAMMATORY ARTHROPATHIES IS ASSOCIATED WITH REDUCTION IN CALPROTECTIN. Journal of Hypertension. ISSN 0263-6352. 28, s. E30–E30.
• Provan, Sella Aarrestad; Angel, Kristin; Semb, Anne Grete; Mowinckel, Petter ; Atar, Dan & Kvien, Tore Kristian (2010). EARLY PREDICTORS OF CARDIOVASCULAR DISEASE (CVD) RISK: A 15-YEAR FOLLOW-UP STUDY OF 108 PATIENTS WITH RHEUMATOID ARTHRITIS (RA). Scandinavian Journal of Rheumatology. ISSN 0300-9742. 39, s. 22–22.
• Provan, Sella Aarrestad; Angel, Kristin; Semb, Anne Grete; Atar, Dan & Kvien, Tore Kristian (2010). Remission Is the Mission: A Population Controlled Study of Cvd Risk Markers in Rheumatoid Arthritis (Ra). Journal of Hypertension. ISSN 0263-6352. 28, s. E5–E6.
• Angel, Kristin; Provan, Sella Aarrestad; Kvien, Tore Kristian & Atar, Dan (2010). Tumor Necrosis Factor - Alpha Antagonists Improve Aortic Stiffness in Patients with Inflammatory Arthropathies: A One Year Controlled Study. Journal of Hypertension. ISSN 0263-6352. 28, s. E173–E173.
• Provan, Sella Aarrestad; Angel, Kristin; Semb, Anne Grete; Agewall, Stefan; Atar, Dan & Kvien, Tore Kristian (2010). EARLY PREDICTORS OF CARDIOVASCULAR DISEASE (CVD) RISK: A 15-YEAR FOLLOW-UP STUDY OF 108 PATIENTS WITH RHEUMATOID ARTHRITIS (RA). Journal of Hypertension. ISSN 0263-6352. 28(Supp. A), s. E165–E165.
• Angel, Kristin; Provan, Sella Aarrestad; Kvien, Tore Kristian & Atar, Dan (2010). Tumor Necrosis Factor-alpha antagonists reduce intima media progression rate and improve aortic stiffness in patients with inflammatory arthropathies: a one year controlled study. European Heart Journal. ISSN 0195-668X. 31(Supp. 1), s. 1023–1023.

Se alle arbeider i Cristin